Atlas Trials

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Clinical trial NCT05088460 · TERMINATED

Trial details

NCT number
NCT05088460
Sponsor
Regeneron Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Familial Partial LipodystrophyMetabolic Abnormalities
Start date
2022-02-28
Primary completion
2023-12-13
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.